title: Strategies for recombinant allergen vaccines and fruitful results from first clinical studies.
abstract: Recombinant DNA technology has delivered the prospect of a new generation of preparations for allergen-specific immunotherapy. The first clinical studies with recombinant allergens have yielded encouraging results, suggesting that there is a good chance that such preparations will become available for use in the routine management of allergic disease.
authors.affiliation: Research and Development, Allergopharma Joachim Ganzer KG, Hermann-Koerner-Strasse 52, D-21465 Reinbek, Germany. oliver.cromwell@allergopharma.de
authors.forename: Oliver
authors.initials: O
authors.lastname: Cromwell
authors.forename: Helmut
authors.initials: H
authors.lastname: Fiebig
authors.forename: Roland
authors.initials: R
authors.lastname: Suck
authors.forename: Helga
authors.initials: H
authors.lastname: Kahlert
authors.forename: Andreas
authors.initials: A
authors.lastname: Nandy
authors.forename: Jens
authors.initials: J
authors.lastname: Kettner
authors.forename: Annemie
authors.initials: A
authors.lastname: Narkus
mesh_terms: D000485:Allergens / Q000276:immunology*; D002986:Clinical Trials as Topic; D003888:Desensitization, Immunologic / Q000379:methods*; D006801:Humans; D011994:Recombinant Proteins / Q000276:immunology*; D014612:Vaccines / Q000276:immunology*
chemical_list: D000485:Allergens; D011994:Recombinant Proteins; D014612:Vaccines